Actos and Bladder Cancer
Bloomberg News reported this week that there may be as many as 10,000 lawsuits forthcoming against Takeda Pharmaceuticals, the manufacturer of the popular diabetes drug Actos. The plaintiffs allege that Actos use for prolonged periods has resulted in bladder cancer. Earlier this year, Takeda pulled Actos from the market in Germany and France, citing the increased cancer risk. No such steps have been taken in the U.S., although the safety information on the product inserts has been revised to reflect the risk of bladder cancer.
The evidence linking Actos to bladder cancer is persuasive, and American regulators found that the risk has been documented in studies sponsored by the drug manufacturer. Colling Gilbert Wright & Carter are representing people who have been diagnosed with bladder cancer after at least one year of documented Actos use. If you or a loved one have been affected by this drug or have questions about another potential pharmaceutical claim, call our law firm for a free consultation.